18 completed, 1 not yet recruiting, 1 recruiting. 6 Phase 3, 5 Phase 1, 5 Phase 2, 4 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 6 | Completed 6 |
| Phase 1 | 5 | Completed 5 |
| Phase 2 | 5 | Completed 5 |
| Phase 4 | 4 | Completed 2, Not yet recruiting 1, Recruiting 1 |
Follow revefenacin: new trials by email Literature Review of revefenacin trials Research Report on revefenacin
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Patients Presenting to the Emergency Department With Acute Exacerbation of COPD (ECOPD) Revefenacin, formoterol fumarate, Placebo (Sterile Normal Saline) - COPD Exacerbation | Phase 4 | Not yet recruiting | University of Tennessee Graduate School of Medicine | 280 | 2026-11-12 | 2026-10-19 |
| Compare the Effects of Nebulizer Versus Inhaler Based Therapy for COPD Using Long-acting Bronchodilators umeclidinium 62.5 µg and vilanterol 25 µg, Revefenacin 175 µg, Formoterol 20 µg, Placebo ( Revefenacin and Formoterol ) - COPD (Chronic Obstructive Pulmonary Disease) | Phase 4 | Recruiting | University of Tennessee Graduate School of Medicine | 72 | 2023-12-05 | 2026-10-19 |
| Phase 4 COPD and Suboptimal Inspiratory Flow Rate Revefenacin, Tiotropium, Revefenacin Placebo - Chronic Obstructive Pulmonary Disease | Phase 4 | Completed | Theravance Biopharma | 404 | 2022-01-07 | 2024-12-20 |
| Revefenacin in Chinese Subjects With Moderate to Very Severe Chronic Obstructive Pulmonary Disease(COPD) Revefenacin 175 mcg in 3 ML Inhalation Solution, Placebo inhalation solution QD - COPD | Phase 3 | Completed | Mylan Pharma UK Ltd. | 258 | 2021-11-10 | 2024-11-01 |
| Fasting Bioavailability Study of Mylan's Revefenacin Inhalation Solution Revefenacin Inhalation Solution - Healthy Volunteers Bioavailability Study | Phase 1 | Completed | Mylan Pharma UK Ltd. | 24 | 2021-09-23 | 2022-04-04 |
| Feasibility, Safety and Efficacy of Nebulized Long-Acting Bronchodilators (Formoterol and Revefenacin) vs. Short-Acting Bronchodilators (Albuterol and Ipratropium) in Hospitalized Patients With AECOPD Revefenacin (YUPELRI) & Formoterol (Perforomist), Albuterol Inhalation Aerosol (short-acting beta-agonists) & Ipratropium Aerosol (short-acting anticholinergic) - COPD Exacerbation | Phase 4 | Completed | University of Tennessee Graduate School of Medicine | 60 | 2020-12-09 | 2026-08-03 |
| Revefenacin in Acute Respiratory Insufficiency in COPD Revefenacin Inhalation Solution [Yupelri], Ipratropium Bromide - COPD, Acute Respiratory Failure | Phase 2 | Completed | University of California, Los Angeles | 21 | 2020-11-01 | 2026-10-14 |
| A 42-day Parallel Group Safety Study of Revefenacin and Formoterol, Administered in Sequence and as a Combination, in Participants With COPD Revefenacin, Placebo, Formoterol - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Mylan Inc. | 122 | 2018-05-31 | 2022-02-24 |
| Revefenacin Peak Inspiratory Flow Rate (PIFR) Study in COPD Revefenacin, Spiriva Handihaler®, Placebo for Revefenacin - Chronic Obstructive Pulmonary Disease, COPD, Low Peak Inspiratory Flow Rate (PIFR) | Phase 3 | Completed | Mylan Inc. | 207 | 2017-03-27 | 2022-02-24 |
| Thorough QT (TQT) Study of TD-4208 in Healthy Subjects TD-4208 175 mcg, TD-4208 700 mcg, Placebo for TD-4208 - Cardiac Repolarization in Healthy Subjects | Phase 1 | Completed | Mylan Inc. | 48 | 2016-05-01 | 2022-02-24 |
| Pharmacokinetics of TD-4208 in Patients With Severe Renal Impairment TD-4208 - Renal Impairment | Phase 1 | Completed | Mylan Inc. | 16 | 2015-12-01 | 2022-02-24 |
| Pharmacokinetics of TD-4208 in Patients With Moderate Hepatic Impairment TD-4208 - Hepatic Impairment | Phase 1 | Completed | Mylan Inc. | 16 | 2015-11-01 | 2022-02-24 |
| Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Mylan Inc. | 611 | 2015-09-01 | 2022-02-24 |
| Efficacy Study of Nebulized TD-4208 for Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Mylan Inc. | 619 | 2015-09-01 | 2022-02-24 |
| A 52-Week Parallel Group Safety Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Tiotropium - Chronic Obstructive Pulmonary Disease (COPD) | Phase 3 | Completed | Mylan Inc. | 1060 | 2015-09-01 | 2022-02-24 |
| TD-4208 Absorption, Distribution, Metabolism and Excretion (ADME) Study in Healthy Male Subjects TD-4208 - Chronic Obstructive Pulmonary Disease (COPD) | Phase 1 | Completed | Mylan Inc. | 9 | 2015-06-01 | 2022-02-24 |
| A 28-Day Parallel Group Study of TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - COPD | Phase 2 | Completed | Mylan Inc. | 355 | 2014-05-01 | 2022-02-24 |
| A 7-Day Cross-over Study of QD (Once Daily) and BID (Twice Daily) TD-4208 in Chronic Obstructive Pulmonary Disease (COPD) TD-4208, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | Mylan Inc. | 64 | 2014-04-01 | 2022-02-24 |
| 7 Days of TD-4208 in Subjects With Chronic Obstructive Pulmonary Disease TD-4208, Placebo - COPD | Phase 2 | Completed | Mylan Inc. | 62 | 2012-12-01 | 2022-02-24 |
| Effects of TD-4208 on FEV1 in Subjects With Chronic Obstructive Pulmonary Disease (COPD) Placebo, TD-4208 700 μg, TD-4208 350 μg - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Completed | Mylan Inc. | 32 | 2011-05-01 | 2022-02-24 |
Pulmonary Disease, Chronic Obstructive (14) · Bronchitis, Chronic (1) · Emphysema (1) · Hepatitis (1) · Liver Cirrhosis (1) · Renal Insufficiency (1)
Mylan Inc. (13) · University of Tennessee Graduate School of Medicine (3) · Mylan Pharma UK Ltd. (2) · Theravance Biopharma (1) · University of California, Los Angeles (1)
United States (16) · China (2) · New Zealand (2)
Andrew Shaw, PhD (1) · Dik WH Ng, PhD (1) · Donald Tashkin, MD (1) · Igor Z Barjaktarevic, MD, PhD (1)
PMID 33124005, PMID 31632000, PMID 32343967, PMID 32393215, PMID 36681255, PMID 38560416, PMID 28987804, PMID 29096627, PMID 31150963, PMID 31647854, PMID 31666076, PMID 39429809, PMID 42548489